Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Breast 1

Conditions

Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Ovarian Neoplasms 1Breast Neoplasms 1

Interventions

Specimen Handling 274Magnetic Resonance Spectroscopy 226pembrolizumab 225Carboplatin 178Biopsy 165Cisplatin 162Nivolumab 157Cyclophosphamide 146Paclitaxel 124Radiotherapy 123Gemcitabine 114Bevacizumab 92durvalumab 91Dexamethasone 87Rituximab 80Oxaliplatin 80venetoclax 73atezolizumab 70Doxorubicin 70Fluorouracil 69Docetaxel 69Capecitabine 68Etoposide 66Radiosurgery 65Ipilimumab 63Radiation 60Prednisone 60Cytarabine 60Lenalidomide 59fludarabine 55

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Bupropion × 90 days × Clear all
NCT03180294 2026-05-19

Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer

NRG Oncology

Phase 2 Completed
230 enrolled 24 charts
BreastGynecologic

Breast Neoplasms, Uterine Cervical Neoplasms, Ovarian Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡